Skip to content


    DEA Class; Rx

    Common Brand Names; Eloxatin

    • Antineoplastics, Alkylating; 
    • Antineoplastics, Platinum Analog

    Non cell-cycle specific, platinum-based alkylating agent
    Used for the treatment of colorectal cancer, in combination with fluorouracil and leucovorin
    Acute or delayed neuropathy can occur; avoid the topical application of ice, as cold temperatures may exacerbate acute neuropathy

    Indicated in combination with infused 5-fluorouracil/leucovorin for adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor and also for treatment of advanced colorectal cancer

    Hypersensitivity to oxaliplatin, other platinum compounds


    • Peripheral neuropathy (76%)
    • Anemia (64%)
    • Nausea (64%)
    • Fatigue (61%)
    • Diarrhea (46%)
    • Vomiting (37%)
    • Abdominal pain (31%)
    • Constipation (31%)
    • Thrombocytopenia (30%)
    • Fever (25%)
    • Anorexia (20%)
    • Leukopenia (13%)
    • Dyspnea (13%)
    • Cough (11%)

    Caution in renal impairment, elderly, neuropathy, neurotoxic agents

    For 3-4 days, avoid contact with ice/cold food/objects, avoid breathing cold air

    Avoid contact with aluminum needles or equipment

    Avoid pregnancy

    Pulmonary fibrosis may occur

    Concomitant use with fluorouracil may increase gastrointestinal effects

    Grade 3 or 4 neutropenia reported in patients with colorectal cancer treated in combination with 5-flurouracil (5-FU) and leucovorin; delay oxaliplatin therapy until neutrophils are at 1.5 x 10^9/L; withhold oxaliplatin for sepsis or septic shock; reduce dose after recovery from Grade 4 neutropenia or febrile neutropenia

    Cardiovascular toxicity reported; ECG monitoring recommended if therapy initiated in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics, and electrolyte abnormalities; correct hypokalemia or hypomagnesemia prior to initiating oxaliplatin and monitor these electrolytes periodically during therapy; avoid oxaliplatin in patients with congenital long QT syndrome

    Reversible posterior leukoencephalopathy syndrome (RPLS, also known as PRES, Posterior Reversible Encephalopathy Syndrome) reported in clinical trials and postmarketing experience

    Based on direct interaction with DNA, therapy can cause fetal harm when administered to a pregnant woman; available human data do not establish presence or absence of major birth defects or miscarriage related to use of drug; advise a pregnant woman of potential hazard to fetus

    There are no data on presence of drug or its metabolites in human or animal milk, effects on breastfed infant or on milk production

    The suggested maximum tolerated dose (MTD) for oxaliplatin is dependent on performance status, other chemotherapy agents or radiation given in combination, and disease state. The dosing of oxaliplatin may vary from protocol to protocol. If questions arise, clinicians should consult the appropriate references to verify the dose.


    130 mg/m2 IV.


    130 mg/m2 IV.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.


    powder for injectable solution

    • 50mg/vial
    • 100mg/vial
    • 200mg/vial